Letters to the Editor

Recombinant von Willebrand Factor (vonicog alfa) reduces platelet inhibition caused by antiplatelet drugs and has potential as an acute haemostatic agent

Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Radcliffe Department of Medicine, University of Oxford; NHS Blood and Transplant, Oxford
Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham
Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; Oxford Cardiovascular Clinical Research Facility (CCRF), John Radcliffe Hospital, Oxford
School of Pharmacy, University of Reading, Reading
Institute for Cardiovascular and Metabolic Research, Harborne Building, University of Reading, Reading
Institute for Cardiovascular and Metabolic Research, Harborne Building, University of Reading, Reading
Institute for Cardiovascular and Metabolic Research, Harborne Building, University of Reading, Reading
School of Pharmacy, University of Reading, Reading
Institute for Cardiovascular and Metabolic Research, Harborne Building, University of Reading, Reading
School of Pharmacy, University of Reading, Reading, UK; Institute for Cardiovascular and Metabolic Research, Harborne Building, University of Reading, Reading
Haematologica Early view Jan 22, 2026 https://doi.org/10.3324/haematol.2025.289179